Found: 10
Select item for more details and to access through your institution.
The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.
- Published in:
- HIV Medicine, 2009, v. 10, n. 8, p. 477, doi. 10.1111/j.1468-1293.2009.00715.x
- By:
- Publication type:
- Article
T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy.
- Published in:
- Biologics: Targets & Therapy, 2008, v. 2, n. 3, p. 577
- By:
- Publication type:
- Article
P02-132 - Evaluation of psychological impact of facial lipoatrophy in HIV: the “assessment of face & body change and distress” questionnaire
- Published in:
- 2010
- By:
- Publication type:
- Abstract
ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
- Published in:
- 2012
- By:
- Publication type:
- journal article
The health equity in all policies (HEiAP) approach before and beyond the Covid-19 pandemic in the Italian context.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
- Published in:
- International Journal of STD & AIDS, 2012, v. 23, n. 7, p. 459, doi. 10.1258/ijsa.2012.011391
- By:
- Publication type:
- Article
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<LT>50 cells/microL)
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
Original Research Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mμL)
- Published in:
- HIV Medicine, 2004, v. 5, n. 1, p. 1, doi. 10.1111/j.1468-1293.2004.00177.x
- By:
- Publication type:
- Article